Ki67 positivity was increased in FFC-fed vehicle treated livers, as has been reported in mouse models of NASH (21, 22) and reduced following treatment with Etrasimod and Amiselimod (Supplementary Figure 6). Here, MKI67 is linked to metabolic dysfunction-associated steatohepatitis.